© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
October 20, 2021
Panelists conclude the discussion with personal insight into the promising future of Alzheimer disease treatment.
October 18, 2021
Expert panelists consider how to define response to disease-modifying therapies and discuss the threshold for treatment ineligibility due to lack of response.
October 13, 2021
A member of the American Brain Foundation discusses the organization’s role in the development of Alzheimer disease management and improvement in education.
October 11, 2021
Key opinion leaders discuss possible ways to mitigate the increased cost of Alzheimer disease treatment.
October 06, 2021
A discussion on the stratification of patient populations for treatment eligibility based on various decision factors.
October 04, 2021
Panelists discuss how to craft future policies for early biomarker detection to use developing therapies that target underlying pathophysiology.
September 29, 2021
Key opinion leaders consider effective ways to improve access to appropriate care for individuals with Alzheimer disease.
September 27, 2021
Expert panelists discuss methods to better monitor comorbidities and adverse effects associated with Alzheimer disease.
September 22, 2021
Experts in the management of Alzheimer disease consider the future goals of therapy in tandem with the development of early detection polices.
September 20, 2021
A discussion on the typical journey of a patient with Alzheimer disease from initial presentation to proper diagnosis within the health care system.